There are three main types of ovarian cancer: epithelial, germ cell, and stromal. Learn about each type’s defining ...

Simply put, tumor markers are anything cancer cells or typical body cells make in response to cancer or noncancerous (benign) conditions. If you have cancer, these markers may be present in your ...

If you just found out that you or your child has a germ cell tumor, you may have a lot of questions about what it means and what comes next. There are many kinds of germ cell tumors, and only some ...

Most esophageal cancers are squamous cell cancers. Therefore a tumor marker for esophageal cancer is supposed to be SCC. However, this tumor marker is not of clear clinical utility and is only ...

Drug Discovery Lab, Department of Chemistry, City University of Hong Kong, 83 Tat Chee Avenue, Hong Kong SAR 999077, People’s Republic of China Department of Chemistry, National University of ...

CAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, ...

A teratoma is a type of germ cell tumour that starts in your reproductive cells, like eggs and sperm. According to experts, most of the teratomas are benign but sometimes they can become malignant as ...

Pure seminoma means that there are no teratoma cells in the tumour. You will have normal Alpha fetoprotein (AFP) marker levels if you have pure seminoma. There are two categories of outlook for pure ...

Get Instant Summarized Text (Gist) The CLEAR study highlights the importance of tumor size reduction in enhancing survival outcomes for advanced renal cell carcinoma (aRCC) patients. The ...

Dr. William Tap led the development of vimseltinib for tenosynovial giant cell tumor. The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare ...

Clinical outcomes of stage IIA/IIB seminoma treated with radiotherapy and chemotherapy: Should regional therapy be considered the preferred treatment approach?